Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Herombopag in Pediatric Chronic ITP
NCT05685420Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of hetrombopag in chronic primary immune thrombocytopenia (ITP), sponsored by Hengrui. Primary endpoints: Percentage of subjects with new myelofibrosis, new cataract, or existing cataract progression up to 7 months, All Adverse Events of Special Interest up to 7 months and 3 more. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05685420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685420.